<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574857</url>
  </required_header>
  <id_info>
    <org_study_id>20455</org_study_id>
    <nct_id>NCT03574857</nct_id>
  </id_info>
  <brief_title>Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance</brief_title>
  <official_title>Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to compare efficacy of metolazone and chlorothiazide as
      add-on therapy in patients refractory to loop diuretics with heart failure with a reduced
      ejection fraction (HFrEF). This will be a single-center randomized pilot study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net urine output at 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Milliliters of urine output minus the oral plus intravenous intake</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Net urine output at 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Milliliters of urine output minus the oral plus IV intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net fluid balance over 12 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>the net fluid balance over 12 and 24 hours prior to the addition of metolazone or chlorothiazide compared to the 12 hours after addition of the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net fluid balance over 24 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Net fluid balance over 24 hours prior to the addition of metolazone or chlorothiazide compared to the 24 hours after addition of the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change</measure>
    <time_frame>48 hours</time_frame>
    <description>Change in documented weight in kg at 48 hours after starting metolazone or chlorothiazide</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Electrolyte disturbances</measure>
    <time_frame>48 hours</time_frame>
    <description>Frequency of hypokalemia, hypomagnesemia, hyponatremia</description>
  </other_outcome>
  <other_outcome>
    <measure>Worsening renal function</measure>
    <time_frame>48 hours</time_frame>
    <description>increase in serum creatinine greater that 0.5 mg/dL from the patient's baseline value on the day of the first dose of chlorothiazide or metolazone</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Assessed until hospital discharge, an average of 7 days</time_frame>
    <description>Number of days hospitalized</description>
  </other_outcome>
  <other_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Assessed until hospital discharge, an average of 7 days</time_frame>
    <description>Number of days patient is located in an ICU</description>
  </other_outcome>
  <other_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Assessed until hospital discharge, an average of 7 days</time_frame>
    <description>Incidence of in-hospital mortality</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Heart Failure</condition>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <condition>Heart Failure Acute</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Metolazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metolazone 5 mg by mouth once daily for 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorothiazide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chlorothiazide 500 mg IV once daily for 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metolazone Oral Tablet</intervention_name>
    <description>Day 1: Metolazone 5 mg PO Day 2: Metolazone 5 mg PO</description>
    <arm_group_label>Metolazone</arm_group_label>
    <other_name>Zaroxolyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorothiazide Injection</intervention_name>
    <description>Day 1: Chlorothiazide 500 mg IV Day 2: Chlorothiazide 500 mg IV</description>
    <arm_group_label>Chlorothiazide</arm_group_label>
    <other_name>Diuril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Admitted for acute decompensated HF with left ventricular ejection fraction (LVEF)
             &lt;40%

          -  Refractory fluid overload:

          -  Unresponsive (&lt;500 mL net negative over previous 24 hours) AND ineffective diuresis
             (determined by HF team) to moderate intensity push or low intensity continuous
             infusion loop diuretic (80 mg IV furosemide or equivalent bumetanide dose of 4 mg)

          -  English or Spanish-speaking subjects

          -  Willing and able to comply with study procedures

        Exclusion Criteria:

          -  Baseline thiazide use prior to admission or prior to study enrollment

          -  Renal replacement therapies (RRT) or glomerular filtration rate (GFR) &lt;30 mL/min at
             the time of enrollment

          -  Pregnant women

          -  Cognitive impairment

          -  Prisoners

          -  Left ventricular assist devices (LVAD) or temporary mechanical circulatory support
             devices

          -  History of cardiac transplant

          -  Reported allergy to thiazides

          -  No enteral access or unable to take medications enterally

          -  Palliative diuretics

          -  Systolic blood pressure (SBP) &lt;90 mm Hg prior to randomization

          -  Patients receiving concomitant lithium therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>June 20, 2018</last_update_submitted>
  <last_update_submitted_qc>June 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Emily Burns</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Loop diuretics</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Diuretic resistance</keyword>
  <keyword>Thiazide diuretics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metolazone</mesh_term>
    <mesh_term>Chlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

